SanBio Company Limited (TYO:4592)

Japan flag Japan · Delayed Price · Currency is JPY
2,368.00
+61.00 (2.64%)
Jul 25, 2025, 3:30 PM JST
2.64%
Market Cap170.53B
Revenue (ttm)n/a
Net Income (ttm)-4.27B
Shares Out72.01M
EPS (ttm)-61.28
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,819,900
Average Volume3,495,850
Open2,330.00
Previous Close2,307.00
Day's Range2,271.00 - 2,386.00
52-Week Range661.00 - 3,935.00
Beta-0.05
RSI50.31
Earnings DateSep 12, 2025

About SanBio Company

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 29
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4592
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.